Repositioning transanal total mesorectal excision in the robotic era Authors: Hui Li, Tong Shen, Xiaojun Shen Published: 2026 ABSTRACT Low rectal cancer lies deep in the pelvis, close to the pelvic autonomic nerves and urogenital structures. Surgery must therefore balance oncological clearance, sphincter preservation, and functional outcomes. Total mesorectal excision (TME) remains the fundamental oncological principle across open, laparoscopic, robotic, and transanal approaches. A deep, narrow male pelvis, obesity, a very low tumor, fibrosis after neoadjuvant treatment, and restricted distal transection can make transabdominal TME technically demanding. Robotic transabdominal TME (rTME) provides three-dimensional high-definition visualization, wristed instruments, tremor filtration, and a stable operating platform. These features address several limitations of conventional laparoscopy. rTME may therefore be suitable for most patients with mid-to-low rectal cancer when distal dissection and transection remain controllable from above. Against this background, the role of transanal total mesorectal excision (TaTME) should be reassessed rather than dismissed. Current evidence neither renders TaTME obsolete nor establishes a universal advantage across all low rectal cancers. Instead, TaTME is better positioned as a selective technical complement for very low tumors, restricted distal exposure or transection, and composite difficult-pelvis scenarios. At the same time, the development of robot-assisted TaTME (R-TaTME), hybrid TaTME, single-port robotic systems, and flexible transanal platforms offers new technological avenues. These platforms may improve procedural stability and instrument dexterity during transanal surgery. This review reappraises TaTME in the robotic era, focusing on indication refinement, pathological quality, training and quality assurance, functional preservation, and platform development.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s11701-026-03885-6. Introduction Low rectal cancer is a demanding surgical problem within a major global disease burden. GLOBOCAN 2024 estimated more than 2.0 million new colorectal cancer cases and approximately 918,000 deaths worldwide [1]. Rectal cancer alone accounted for 778,594 new cases and 339,370 deaths in the 2024 International Agency for Research on Cancer estimates [2]. Unlike colon cancer, mid-to-low rectal cancer is treated within the confined pelvis. The operative route can therefore influence sphincter preservation and bowel and genitourinary function as well as oncological clearance. The distinctive burden of low rectal cancer arises from the trade-off between radical resection and long-term function. As tumor height decreases, distal margin control becomes more difficult and dissection approaches the anal sphincter complex, pelvic autonomic nerves, urogenital organs, and pelvic floor. Some patients with very low tumors still require abdominoperineal resection and a permanent stoma. Even after sphincter-preserving surgery, LARS, urgency, increased stool frequency, urinary dysfunction, and sexual dysfunction may persist [3–5]. NCCN and ESMO guidance accordingly places organ preservation, baseline function, treatment-related morbidity, and quality of life within the treatment decision [3, 4]. Functional preservation should therefore be treated as part of oncological decision-making rather than as a secondary consideration. The meta-analysis by Croese et al. found that LARS is common after oncological rectal resection and identified low anastomosis and previous radiotherapy as important risk factors [5]. Accordingly, the clinical objective is not tumor removal alone but a defensible balance among oncological control, sphincter preservation, and durable function. These competing priorities provide the clinical basis for reassessing the respective roles of transabdominal and transanal approaches to TME. TME principles and the difficult pelvis: the deep-pelvic limits of a transabdominal route TME provides the common oncological standard against which every operative route should be judged. Heald and colleagues highlighted the role of the mesorectum in pelvic recurrence in 1982 [6], and MacFarlane et al. subsequently helped standardize sharp dissection along the mesorectal fascial plane [7]. The operative objectives are an intact mesorectal specimen, a clear CRM, adequate distal clearance, and preservation of the pelvic autonomic nerves [6, 7]. Open, laparoscopic, robotic, and transanal procedures are therefore alternative ways to deliver the same oncological dissection principle, not different standards of radical surgery. The need for alternative access arises because transabdominal laparoscopy does not reproduce deep-pelvic TME equally well in every patient. COLOR II reported similar 3-year locoregional recurrence and survival after laparoscopic and open surgery [8]. However, ACOSOG Z6051 and ALaCaRT did not establish noninferiority of laparoscopy for their composite pathological endpoints [9, 10]. These findings do not invalidate laparoscopic TME, but they show that access-related constraints can affect pathological quality and reproducibility. Robotic and transanal approaches were developed in response to this unresolved technical limitation. Anatomical terminology must remain study-specific when this evidence is interpreted. In this review, mid-to-low rectal cancer generally refers to tumors with a distal edge within 10 cm of the anal verge, consistent with the cited studies [11–14]. A very low tumor is defined by a distal edge ≤ 5 cm from the anal verge in most studies, although some use nearby numerical thresholds or anatomical criteria, such as proximity to the anorectal ring or an expected ultralow anastomosis. Tumor height should therefore be interpreted alongside preoperative magnetic resonance imaging and intraoperative anatomy. The difficult pelvis is best understood as a composite operative constraint rather than a single anatomical diagnosis. Relevant factors include a deep, narrow male pelvis, obesity, a very low, anterior, or bulky tumor, a threatened margin, post-neoadjuvant fibrosis, and previous pelvic surgery. No factor alone constitutes an indication for TaTME. The clinically relevant problem arises when several factors converge and materially restrict distal exposure, dissection, or transection. Risk assessment should therefore integrate anatomy, tumor characteristics, previous treatment, surgeon experience, and institutional capability [11, 12]. Table 1 translates this composite definition into an evidence-informed approach-selection framework. It summarizes anatomical, tumor-related, and treatment-related constraints reported across reviews, trials, and registries [11–15]. The table is not a list of absolute indications, because definitions and evidence strength vary and no single factor consistently justifies TaTME. Table 1Difficult-pelvis factors and implications for TME approach selectionDifficult factorMain effect on transabdominal TMEPotential contribution of rTMEImplication for TaTME/R-TaTMEDeep, narrow male pelvis [11–13]Restricted deep-pelvic exposure; difficult distal dissection, transection, and stapler placementThree-dimensional vision and wristed instruments may facilitate precise deep-pelvic dissectionConsider a transanal route only when distal rectal control remains restricted; requires an experienced centerObesity [11–13]Pelvic fat impairs traction, exposure, and recognition of the correct planeStable traction and articulated dissection may reduce transabdominal difficultyObesity alone is not an indication; TaTME may be considered if substantive distal difficulty persistsVery low, anterior, or bulky tumor [12, 14, 16]More difficult distal-margin control, sphincter preservation, and low transectionMay improve low pelvic dissection, although stapler angulation can remain limitingDirect distal visualization and controlled transection may be valuable in carefully selected casesPost-neoadjuvant fibrosis [11, 15]Obscured planes and more difficult nerve-preserving dissectionMagnified vision and instrument articulation may assist plane recognitionBidirectional dissection may assist orientation, but evidence is mainly experientialPrevious pelvic surgery or adhesions [11]Unclear planes with increased risk of bleeding, perforation, or conversionBenefit depends on the extent of adhesions and team experienceEvidence is insufficient; individualize and avoid during the early learning phaseR-TaTME, robot-assisted TaTME; rTME, robotic transabdominal TME; TaTME, transanal TME; TME, total mesorectal excision. The evidence concerning previous pelvic surgery or adhesions is particularly limited. Previous pelvic surgery or adhesions are retained only as modifiers within a composite difficult-pelvis assessment and should not be interpreted as an independent indication for TaTME Table 1Difficult-pelvis factors and implications for TME approach selectionDifficult factorMain effect on transabdominal TMEPotential contribution of rTMEImplication for TaTME/R-TaTMEDeep, narrow male pelvis [11–13]Restricted deep-pelvic exposure; difficult distal dissection, transection, and stapler placementThree-dimensional vision and wristed instruments may facilitate precise deep-pelvic dissectionConsider a transanal route only when distal rectal control remains restricted; requires an experienced centerObesity [11–13]Pelvic fat impairs traction, exposure, and recognition of the correct planeStable traction and articulated dissection may reduce transabdominal difficultyObesity alone is not an indication; TaTME may be considered if substantive distal difficulty persistsVery low, anterior, or bulky tumor [12, 14, 16]More difficult distal-margin control, sphincter preservation, and low transectionMay improve low pelvic dissection, although stapler angulation can remain limitingDirect distal visualization and controlled transection may be valuable in carefully selected casesPost-neoadjuvant fibrosis [11, 15]Obscured planes and more difficult nerve-preserving dissectionMagnified vision and instrument articulation may assist plane recognitionBidirectional dissection may assist orientation, but evidence is mainly experientialPrevious pelvic surgery or adhesions [11]Unclear planes with increased risk of bleeding, perforation, or conversionBenefit depends on the extent of adhesions and team experienceEvidence is insufficient; individualize and avoid during the early learning phaseR-TaTME, robot-assisted TaTME; rTME, robotic transabdominal TME; TaTME, transanal TME; TME, total mesorectal excision. The evidence concerning previous pelvic surgery or adhesions is particularly limited. Previous pelvic surgery or adhesions are retained only as modifiers within a composite difficult-pelvis assessment and should not be interpreted as an independent indication for TaTME Difficult-pelvis factors and implications for TME approach selection R-TaTME, robot-assisted TaTME; rTME, robotic transabdominal TME; TaTME, transanal TME; TME, total mesorectal excision. The evidence concerning previous pelvic surgery or adhesions is particularly limited. Previous pelvic surgery or adhesions are retained only as modifiers within a composite difficult-pelvis assessment and should not be interpreted as an independent indication for TaTME Against this background, the key question is not whether rTME or TaTME is universally superior, but how advances in robotic transabdominal surgery redefine the circumstances in which a transanal route provides meaningful technical value. This structured narrative review synthesizes evidence on rTME, TaTME performed within structured quality-assurance frameworks, and emerging robot-assisted transanal platforms, with emphasis on pathological quality, patient selection, implementation, functional outcomes, and the limitations of current comparative evidence. We propose an evidence-informed framework in which rTME may narrow the routine role of conventional TaTME, whereas TaTME retains selective value when substantive distal technical constraints remain. Methods Review design and search strategy This study was conducted as a structured narrative review because the review question spans comparative effectiveness, implementation, function, and emerging technology. PubMed/MEDLINE, Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials were searched for English-language publications from 1 January 1982 to 11 August 2026. The lower date boundary was set at 1982 because this was the year of the foundational publication on TME [6]. Database searches combined controlled vocabulary, where available, with free-text terms for rectal cancer, total mesorectal excision, robotic surgery, transanal surgery, and the difficult pelvis. Terms included “rectal cancer,” “rectal neoplasm,” “total mesorectal excision,” “robotic TME,” “robot-assisted TME,” “transanal TME,” “TaTME,” “robot-assisted TaTME,” “single-port,” “hybrid,” and “difficult pelvis,” with spelling variants and Boolean combinations. Reference lists and official websites of relevant professional societies and guideline organizations were also searched. Database-specific strategies and limits are reported in Supplementary Table S1. Eligibility, selection, and data extraction Eligible publications evaluated adults undergoing TME for rectal adenocarcinoma and addressed rTME, TaTME, R-TaTME, hybrid TaTME, or single-port robotic transanal approaches. Pathological outcomes included CRM and DRM status, R0 resection, lymph-node yield, and source-defined TME specimen completeness. Other outcomes included perioperative and oncological results, function, training, learning curves, and quality assurance. Randomized controlled trials, systematic reviews, meta-analyses, clinical guidelines, registry studies, and comparative cohort studies were prioritized. Small case series were considered only for emerging robot-assisted, hybrid, or single-port transanal platforms for which higher-level clinical evidence was unavailable. Non-English publications, nonclinical studies, studies involving benign disease, mixed colorectal series without separately extractable rectal-cancer data, and reports without outcomes relevant to the review question were excluded. Records were assessed for relevance to predefined themes and for the level and completeness of evidence. When cohorts overlapped, the larger or more complete report was preferred. Companion publications were retained only when they supplied distinct outcomes or longer follow-up. For Tables 2, 3 and 4, full texts and supplements were checked against a predefined data matrix. The matrix included study design, sample size, CRM and DRM status, R0 resection, lymph-node yield, and source-defined TME specimen quality. Values and outcome-specific denominators were transcribed as reported and cross-checked against the original reports. Heterogeneous definitions and reporting formats precluded pooling or indirect statistical comparisons. Table 2Pathological-quality outcomes from randomized trials, large multicenter cohorts, and direct comparative studies of rTMEStudy (year)Group and study designCRM positiveDRMR0 resectionLymph node yieldTME specimen quality, as defined in the original studyROLARR (2017) [20]n = 237 randomize; RCT5.1% (12/235 evaluable)NRNRNRNRKim et al. (2018) [29]rTME n = 73; LapTME n = 66; RCTNR1.5 cm (0.04–6.7)NR18 (7–59)Complete 80.3%; near-complete 18.2%; incomplete 1.5%Lee et al. (2019) [30]n = 370; matched6.0%Positive 0.3%NRNRComplete/near-complete 99.2%Buan et al. (2021) [31]n = 384 (10.8%)1.65 cm (0.2–7.2)97.4% (37/38)13 (0–28)94.7% (36/38)REAL (2022) [21]n = 586; RCT4.0% (22/547)NRNRNRMacroscopically complete 95.4% (559/586)de’Angelis et al. (2024) [32]n = 148; PSM8.8% (13/148)Positive 2.0% (3/148)NR (R1 8.8%)15.1 ± 6.497.3%TARO (2024) [34]rTME n = 54; single-center RCT; conference abstract0/54Positive 0/54NR15Complete 51/54 (94.4%)RESET (2026) [24]n = 458; prospective high-risk cohort1.8%17 mm (8–30)95.8%16 (11–23)Grade III (complete) 89.7%RESOLUTION (2025) [26]weighted n = 1,057.5; multicenter cohort3.7%NR96.6%16 (12–22)86.0%EUREKA (2025) [27]n = 1,390; international multicenter cohort69 (5.5%)NR1,296 (94.7%)17.3 ± 8.9Complete 81.9%; near-complete 13.1%Lin et al. (2026) [33]n = 37; PSM5.4% (2/37)Positive 0; 1.5 cm (0.7–2.1)NR18 (16–20)NRCRM, circumferential resection margin; DRM, distal resection margin; NR, not reported; PSM, propensity-score matching; RCT, randomized controlled trial; TME, total mesorectal excision. Values are retained as reported in the original studies. ROLARR is included as the pivotal pre-2018 randomized trial; only directly reported pathological endpoints are shown. For RESOLUTION, weighted values are shown; for RESET, unadjusted approach-specific pathological values are shown. Definitions and evaluable denominators differed across studies. RESOLUTION and EUREKA include partially overlapping center datasets and should not be interpreted as independent patient cohorts. The final column retains each study’s original pathological category; complete, complete/near-complete, macroscopically complete, and grade III outcomes are not treated as interchangeable. For EUREKA, counts and percentages are reproduced as published without calculating additional denominators. For Kim et al. 73 patients were analyzed in the robotic arm and 66 in the laparoscopic comparator arm; the latter is not a pathological-data denominator for the robotic cohort. TARO has been reported only as a conference abstract; detailed full-text appraisal was therefore not possible Table 2Pathological-quality outcomes from randomized trials, large multicenter cohorts, and direct comparative studies of rTMEStudy (year)Group and study designCRM positiveDRMR0 resectionLymph node yieldTME specimen quality, as defined in the original studyROLARR (2017) [20]n = 237 randomize; RCT5.1% (12/235 evaluable)NRNRNRNRKim et al. (2018) [29]rTME n = 73; LapTME n = 66; RCTNR1.5 cm (0.04–6.7)NR18 (7–59)Complete 80.3%; near-complete 18.2%; incomplete 1.5%Lee et al. (2019) [30]n = 370; matched6.0%Positive 0.3%NRNRComplete/near-complete 99.2%Buan et al. (2021) [31]n = 384 (10.8%)1.65 cm (0.2–7.2)97.4% (37/38)13 (0–28)94.7% (36/38)REAL (2022) [21]n = 586; RCT4.0% (22/547)NRNRNRMacroscopically complete 95.4% (559/586)de’Angelis et al. (2024) [32]n = 148; PSM8.8% (13/148)Positive 2.0% (3/148)NR (R1 8.8%)15.1 ± 6.497.3%TARO (2024) [34]rTME n = 54; single-center RCT; conference abstract0/54Positive 0/54NR15Complete 51/54 (94.4%)RESET (2026) [24]n = 458; prospective high-risk cohort1.8%17 mm (8–30)95.8%16 (11–23)Grade III (complete) 89.7%RESOLUTION (2025) [26]weighted n = 1,057.5; multicenter cohort3.7%NR96.6%16 (12–22)86.0%EUREKA (2025) [27]n = 1,390; international multicenter cohort69 (5.5%)NR1,296 (94.7%)17.3 ± 8.9Complete 81.9%; near-complete 13.1%Lin et al. (2026) [33]n = 37; PSM5.4% (2/37)Positive 0; 1.5 cm (0.7–2.1)NR18 (16–20)NRCRM, circumferential resection margin; DRM, distal resection margin; NR, not reported; PSM, propensity-score matching; RCT, randomized controlled trial; TME, total mesorectal excision. Values are retained as reported in the original studies. ROLARR is included as the pivotal pre-2018 randomized trial; only directly reported pathological endpoints are shown. For RESOLUTION, weighted values are shown; for RESET, unadjusted approach-specific pathological values are shown. Definitions and evaluable denominators differed across studies. RESOLUTION and EUREKA include partially overlapping center datasets and should not be interpreted as independent patient cohorts. The final column retains each study’s original pathological category; complete, complete/near-complete, macroscopically complete, and grade III outcomes are not treated as interchangeable. For EUREKA, counts and percentages are reproduced as published without calculating additional denominators. For Kim et al. 73 patients were analyzed in the robotic arm and 66 in the laparoscopic comparator arm; the latter is not a pathological-data denominator for the robotic cohort. TARO has been reported only as a conference abstract; detailed full-text appraisal was therefore not possible Pathological-quality outcomes from randomized trials, large multicenter cohorts, and direct comparative studies of rTME CRM, circumferential resection margin; DRM, distal resection margin; NR, not reported; PSM, propensity-score matching; RCT, randomized controlled trial; TME, total mesorectal excision. Values are retained as reported in the original studies. ROLARR is included as the pivotal pre-2018 randomized trial; only directly reported pathological endpoints are shown. For RESOLUTION, weighted values are shown; for RESET, unadjusted approach-specific pathological values are shown. Definitions and evaluable denominators differed across studies. RESOLUTION and EUREKA include partially overlapping center datasets and should not be interpreted as independent patient cohorts. The final column retains each study’s original pathological category; complete, complete/near-complete, macroscopically complete, and grade III outcomes are not treated as interchangeable. For EUREKA, counts and percentages are reproduced as published without calculating additional denominators. For Kim et al. 73 patients were analyzed in the robotic arm and 66 in the laparoscopic comparator arm; the latter is not a pathological-data denominator for the robotic cohort. TARO has been reported only as a conference abstract; detailed full-text appraisal was therefore not possible Table 3Pathological-quality outcomes from randomized trials, large registries, prospective cohorts, and direct comparative studies of TaTMEStudy (year)Group and study designCRM positiveDRMR0 resectionLymph node yieldTME specimen quality, as defined in the original studyInternational TaTME Registry (2017) [12]n = 634 rectal cancers (720 total cases); registry14 (2.4%)Positive: 2 (0.3%); median 15 mmNR (R1 2.7%)16.5 ± 9.2Intact 85.0%; intact/minor defects 96.0%de Lacy et al. (2018) [46]n = 1868.1% (15/186)Positive 3.2% (6/186)NR14 (11–18)95.7% (178/186)International TaTME Registry (2019) [37]n = 2,6534.0%Positive 1.0%NRNRComplete/near-complete 91.2%Lee et al. (2019) [30]n = 226; matched5.6%Positive 1.8%NRNRComplete/near-complete 99.1%Simo et al. (2021) [43]n = 173; prospective multicenter cohort1.4%Positive 1.1%NRNR72.8%Buan et al. (2021) [31]n = 422.4% (1/42)2.50 cm (0.3–10.0)95.2% (40/42)14.5 (2–28)Complete: 37 (90.2%)Ta-LaTME (2023) [40]n = 55; mITT; RCT0/44 evaluableMedian 18.5 mm (IQR 10); <10 mm in 7/55 (12.7%; not equivalent to a positive DRM)NR15 (IQR 8)100% (55/55)de’Angelis et al. (2024) [32]n = 148; PSM3.4% (5/148)Positive 0NR (R1 3.4%)12.9 ± 5.782.4%TARO (2024) [34]TaTME n = 54; single-center RCT; conference abstract0/54Positive 0/54NR17Complete 53/54 (98.1%)RESET (2026) [24]n = 158; prospective high-risk cohort1.9%15 mm (10–30)94.2%13 (10–21)Grade III (complete) 80.6%TaLaR (2025) [14]n = 544; RCT0.9% (5/544)Positive 0.4% (2/544)NR14 (10–19)Complete: 487 (89.5%); near-complete: 57 (10.5%); incomplete: 0COLOR III (2026) [41]n = 711; mITT; RCT1% (4/611)Positive 1% (7/690)NRNRMacroscopically complete 84% (583/692)Lin et al. (2026) [33]n = 37; PSM2.7% (1/37)Positive 0; 1.8 cm (1.3–2.5)NR18 (15.5–23.5)NRCRM, circumferential resection margin; DRM, distal resection margin; mITT, modified intention-to-treat; NR, not reported; PSM, propensity-score matching; RCT, randomized controlled trial; TME, total mesorectal excision. Values are retained as reported by the original investigators. The 2017 and 2019 international-registry reports contain overlapping patients and are included to show the development from early implementation to the larger pathological-risk analysis, not as independent cohorts. Ta-LaTME used a distal-margin threshold of < 10 mm, which is not equivalent to a microscopically positive DRM. RESET values are unadjusted approach-specific pathological outcomes. Rows derived from the same comparative study represent different operative arms and should not be counted as independent studies. The final column preserves the specimen-quality definition used by each source. COLOR III used a modified intention-to-treat cohort of 711 TaTME patients. Denominators differ because each pathological endpoint was reported among patients or specimens with evaluable data for that endpoint (CRM, n = 611; DRM, n = 690; macroscopic specimen completeness, n = 692). TARO has been reported only as a conference abstract; detailed full-text appraisal was therefore not possible Table 3Pathological-quality outcomes from randomized trials, large registries, prospective cohorts, and direct comparative studies of TaTMEStudy (year)Group and study designCRM positiveDRMR0 resectionLymph node yieldTME specimen quality, as defined in the original studyInternational TaTME Registry (2017) [12]n = 634 rectal cancers (720 total cases); registry14 (2.4%)Positive: 2 (0.3%); median 15 mmNR (R1 2.7%)16.5 ± 9.2Intact 85.0%; intact/minor defects 96.0%de Lacy et al. (2018) [46]n = 1868.1% (15/186)Positive 3.2% (6/186)NR14 (11–18)95.7% (178/186)International TaTME Registry (2019) [37]n = 2,6534.0%Positive 1.0%NRNRComplete/near-complete 91.2%Lee et al. (2019) [30]n = 226; matched5.6%Positive 1.8%NRNRComplete/near-complete 99.1%Simo et al. (2021) [43]n = 173; prospective multicenter cohort1.4%Positive 1.1%NRNR72.8%Buan et al. (2021) [31]n = 422.4% (1/42)2.50 cm (0.3–10.0)95.2% (40/42)14.5 (2–28)Complete: 37 (90.2%)Ta-LaTME (2023) [40]n = 55; mITT; RCT0/44 evaluableMedian 18.5 mm (IQR 10); <10 mm in 7/55 (12.7%; not equivalent to a positive DRM)NR15 (IQR 8)100% (55/55)de’Angelis et al. (2024) [32]n = 148; PSM3.4% (5/148)Positive 0NR (R1 3.4%)12.9 ± 5.782.4%TARO (2024) [34]TaTME n = 54; single-center RCT; conference abstract0/54Positive 0/54NR17Complete 53/54 (98.1%)RESET (2026) [24]n = 158; prospective high-risk cohort1.9%15 mm (10–30)94.2%13 (10–21)Grade III (complete) 80.6%TaLaR (2025) [14]n = 544; RCT0.9% (5/544)Positive 0.4% (2/544)NR14 (10–19)Complete: 487 (89.5%); near-complete: 57 (10.5%); incomplete: 0COLOR III (2026) [41]n = 711; mITT; RCT1% (4/611)Positive 1% (7/690)NRNRMacroscopically complete 84% (583/692)Lin et al. (2026) [33]n = 37; PSM2.7% (1/37)Positive 0; 1.8 cm (1.3–2.5)NR18 (15.5–23.5)NRCRM, circumferential resection margin; DRM, distal resection margin; mITT, modified intention-to-treat; NR, not reported; PSM, propensity-score matching; RCT, randomized controlled trial; TME, total mesorectal excision. Values are retained as reported by the original investigators. The 2017 and 2019 international-registry reports contain overlapping patients and are included to show the development from early implementation to the larger pathological-risk analysis, not as independent cohorts. Ta-LaTME used a distal-margin threshold of < 10 mm, which is not equivalent to a microscopically positive DRM. RESET values are unadjusted approach-specific pathological outcomes. Rows derived from the same comparative study represent different operative arms and should not be counted as independent studies. The final column preserves the specimen-quality definition used by each source. COLOR III used a modified intention-to-treat cohort of 711 TaTME patients. Denominators differ because each pathological endpoint was reported among patients or specimens with evaluable data for that endpoint (CRM, n = 611; DRM, n = 690; macroscopic specimen completeness, n = 692). TARO has been reported only as a conference abstract; detailed full-text appraisal was therefore not possible Pathological-quality outcomes from randomized trials, large registries, prospective cohorts, and direct comparative studies of TaTME CRM, circumferential resection margin; DRM, distal resection margin; mITT, modified intention-to-treat; NR, not reported; PSM, propensity-score matching; RCT, randomized controlled trial; TME, total mesorectal excision. Values are retained as reported by the original investigators. The 2017 and 2019 international-registry reports contain overlapping patients and are included to show the development from early implementation to the larger pathological-risk analysis, not as independent cohorts. Ta-LaTME used a distal-margin threshold of < 10 mm, which is not equivalent to a microscopically positive DRM. RESET values are unadjusted approach-specific pathological outcomes. Rows derived from the same comparative study represent different operative arms and should not be counted as independent studies. The final column preserves the specimen-quality definition used by each source. COLOR III used a modified intention-to-treat cohort of 711 TaTME patients. Denominators differ because each pathological endpoint was reported among patients or specimens with evaluable data for that endpoint (CRM, n = 611; DRM, n = 690; macroscopic specimen completeness, n = 692). TARO has been reported only as a conference abstract; detailed full-text appraisal was therefore not possible Table 4Pathological-quality outcomes of early robot-assisted or hybrid TaTME studiesStudy (year)GroupCRM positiveDRMR0 resectionLymph node yieldTME specimen quality, as defined in the original studyMonsellato et al. (2019) [49]R-TaTME; n = 30/3Negative in 3/3NRNR3/3; Quirke grade 3Hu et al. (2020) [47]R-TaTME; n = 2015% (3/20)3.1 ± 1.3 cmNR18.7 ± 6.3Complete 90%; complete/near-complete 100%Ye et al. (2021) [50]R-TaTME; n = 1302.0 cm (1.5–2.5)NR15 (13–16)Complete 61.5%; complete/near-complete 100%Marks et al. (2021) [48]SP rTaTME; n = 2Negative margins reported; CRM not separately quantifiedNot separately quantifiedNRNRComplete TME in 2/2Ando et al. (2023) [51]Hybrid TaTME; n = 27; PSM3.7% (1/27), radial marginPositive 3.7% (1/27)96.3% (26/27)15NRCRM, circumferential resection margin; DRM, distal resection margin; NR, not reported; PSM, propensity-score matching; R-TaTME, robot-assisted transanal total mesorectal excision; RM, radial margin; SP, single-port; TME, total mesorectal excision. Hybrid TaTME denotes robotic transabdominal surgery combined with transanal TME. The studies by Monsellato, Hu, Ye, and Marks were early single-center series, whereas Ando et al. performed a retrospective PSM study; sample size, platform, and two-team configuration differed substantially. Monsellato et al. reported only three patients, and Quirke grade 3 is retained as reported. A combined complete/near-complete TME rate is not equivalent to a separately reported complete-TME rate. In the two-patient SP rTaTME report, negative margins were reported without sufficient separate information to assign CRM, DRM, and R0 outcomes; these fields are therefore presented conservatively Table 4Pathological-quality outcomes of early robot-assisted or hybrid TaTME studiesStudy (year)GroupCRM positiveDRMR0 resectionLymph node yieldTME specimen quality, as defined in the original studyMonsellato et al. (2019) [49]R-TaTME; n = 30/3Negative in 3/3NRNR3/3; Quirke grade 3Hu et al. (2020) [47]R-TaTME; n = 2015% (3/20)3.1 ± 1.3 cmNR18.7 ± 6.3Complete 90%; complete/near-complete 100%Ye et al. (2021) [50]R-TaTME; n = 1302.0 cm (1.5–2.5)NR15 (13–16)Complete 61.5%; complete/near-complete 100%Marks et al. (2021) [48]SP rTaTME; n = 2Negative margins reported; CRM not separately quantifiedNot separately quantifiedNRNRComplete TME in 2/2Ando et al. (2023) [51]Hybrid TaTME; n = 27; PSM3.7% (1/27), radial marginPositive 3.7% (1/27)96.3% (26/27)15NRCRM, circumferential resection margin; DRM, distal resection margin; NR, not reported; PSM, propensity-score matching; R-TaTME, robot-assisted transanal total mesorectal excision; RM, radial margin; SP, single-port; TME, total mesorectal excision. Hybrid TaTME denotes robotic transabdominal surgery combined with transanal TME. The studies by Monsellato, Hu, Ye, and Marks were early single-center series, whereas Ando et al. performed a retrospective PSM study; sample size, platform, and two-team configuration differed substantially. Monsellato et al. reported only three patients, and Quirke grade 3 is retained as reported. A combined complete/near-complete TME rate is not equivalent to a separately reported complete-TME rate. In the two-patient SP rTaTME report, negative margins were reported without sufficient separate information to assign CRM, DRM, and R0 outcomes; these fields are therefore presented conservatively Pathological-quality outcomes of early robot-assisted or hybrid TaTME studies CRM, circumferential resection margin; DRM, distal resection margin; NR, not reported; PSM, propensity-score matching; R-TaTME, robot-assisted transanal total mesorectal excision; RM, radial margin; SP, single-port; TME, total mesorectal excision. Hybrid TaTME denotes robotic transabdominal surgery combined with transanal TME. The studies by Monsellato, Hu, Ye, and Marks were early single-center series, whereas Ando et al. performed a retrospective PSM study; sample size, platform, and two-team configuration differed substantially. Monsellato et al. reported only three patients, and Quirke grade 3 is retained as reported. A combined complete/near-complete TME rate is not equivalent to a separately reported complete-TME rate. In the two-patient SP rTaTME report, negative margins were reported without sufficient separate information to assign CRM, DRM, and R0 outcomes; these fields are therefore presented conservatively Results Robotic transabdominal TME: technical advantages and evidence boundaries rTME is most relevant when the principal obstacle is deep-pelvic access from above. Three-dimensional magnified vision, wristed instruments, tremor filtration, a stable camera, and improved ergonomics can facilitate precise dissection in a confined pelvis [11, 16]. These features create a strong technical rationale, but their clinical value must be defined by comparative outcomes rather than by platform capability alone. Early robotic studies established feasibility rather than contemporary comparative effectiveness. A 36-patient pilot randomized trial and a 143-patient three-center cohort reported acceptable short-term pathological outcomes after robot-assisted tumor-specific mesorectal excision [17, 18]. Both studies predated current platforms, credentialing pathways, and standardized reporting. Accordingly, they document procedural development but cannot define the present role of rTME. ROLARR first showed that technical promise did not translate into a universal advantage over laparoscopy. Among 471 randomized patients, conversion occurred in 8.1% after robotic surgery and 12.2% after conventional laparoscopy, without a statistically significant difference [19]. Possible benefits in men and patients with obesity arose from secondary analyses for which the trial was not powered. The greater laparoscopic experience of many participating surgeons also complicates interpretation. ROLARR therefore supports feasibility while leaving any benefit dependent on patient and operator context [19]. REAL materially strengthened the evidence for selected advantages of rTME over laparoscopy. Its short-term analysis reported faster gastrointestinal recovery, a shorter hospital stay, fewer abdominoperineal resections, fewer conversions, and a higher rate of macroscopically complete resection after rTME [20]. At 3 years, disease-free survival was 87.2% after rTME and 83.6% after laparoscopic TME, whereas overall survival was similar [21]. Urinary and sexual outcomes favored rTME at selected time points [21]. These findings support rTME for many mid-to-low rectal cancers, but REAL did not compare rTME with TaTME or prespecify composite difficult-pelvis phenotypes [20, 21]. Accordingly, it cannot show that a robotic transabdominal route resolves every substantive distal constraint. Randomized evidence also supports improved resection quality relative to laparoscopy, although the long-term signal remains less certain. An RCT-only meta-analysis of four trials and 1,952 patients associated rTME with lower CRM positivity, more complete TME specimens, and fewer conversions [22]. It also suggested lower 3-year locoregional recurrence and a modest disease-free survival benefit [22]. Large observational cohorts extend randomized evidence to broader and more complex patient populations, although they cannot establish route-specific causality. In RESET, the adjusted composite outcome of oncological events and major morbidity did not differ among minimally invasive approaches in 1,078 high-risk patients [23]. Among 633 patients with MRI-defined low rectal cancer treated at 11 high-volume centers, TME quality, R1 resection, recurrence, and survival comparable among the operative approaches used across participating centers [24]. Threatened mesorectal fascia, rather than operative platform, independently predicted CRM involvement [24]. RESOLUTION and EUREKA reported source-defined complete-TME rates of 86.0% and 81.9%, respectively [25, 26]. Taken together, these cohorts support acceptable real-world pathological performance of rTME in experienced centers, while suggesting that case selection and margin risk may be at least as important as platform choice. Long-term RESOLUTION follow-up further separates pathological quality from proven survival benefit. Among 1,077 patients with at least 3 years of follow-up, propensity-weighted analysis found more complete TME specimens after rTME [27]. However, 3-year disease-free survival, overall survival, local recurrence, and systemic recurrence did not differ significantly [27]. Because treatment allocation remained observational, these findings indicate no detected survival difference after adjustment rather than equivalence between approaches. Table 2 maps the pathological evidence supporting rTME and its limitations. It includes the pivotal ROLARR trial, later randomized studies, a prospective high-risk cohort, large multicenter cohorts, and direct comparative studies [19, 20, 23, 25, 26, 28–33]. Major designs were retained irrespective of whether results favored rTME. Source-specific definitions, pathology workflows, and denominators should not be pooled across rows. Table 2 shows that rTME can achieve acceptable pathological quality across randomized and multicenter settings. CRM positivity was low in most datasets, and source-defined complete-TME rates ranged from 80.3% to 97.3% [19, 20, 23, 25, 26, 28–32]. These findings support rTME when distal dissection and transection remain feasible from above. However, they do not establish whether TaTME provides additional value when substantive distal technical constraints persist. Development and controversies of TaTME: from direct distal visualization to evidence-based validation TaTME is best understood as a distal access solution that preserves the oncological principles of TME. Its bottom-up dissection was developed to address difficult distal exposure, transection, and margin control through the abdomen. Following the first clinical report in 2010 [34], the evidence base progressed from case series to registries, prospective cohorts, systematic reviews, and randomized trials. The clinical acceptability of TaTME has developed together with formal standardization. A structured curriculum published in 2017 defined prerequisites and core training elements [35]. International expert guidance in 2020 added indications, center organization, quality measures, and implementation requirements [36]. These documents frame TaTME as a program requiring governance, not merely an operative maneuver. Registry evidence supports implementation feasibility but also shows that outcomes are linked to case mix and technical quality. The first 720 international registry cases described short-term safety and procedure-specific complications [12]. An expanded analysis of 2,653 rectal cancers reported CRM positivity of 4.0%, DRM positivity of 1.0%, and complete or near-complete TME in 91.2% [37]. A later analysis reported a 2-year local-recurrence rate of 3% and identified stage, CRM status, and TME quality as associated factors [38]. Because these reports contain overlapping observational populations, they inform implementation and risk rather than independent comparative effects. The Norwegian suspension illustrates why implementation cannot be separated from procedural safety. An unexpected local-recurrence pattern prompted suspension of the national TaTME program [39]. The report did not prove intrinsic procedural harm. Nevertheless, it showed that surveillance, training maturity, case selection, and institutional oversight are central to safe dissemination. The first randomized evidence suggested an access advantage under experienced-team conditions, but it was not definitive. In the Ta-LaTME trial, 116 patients were randomized and 105 entered the modified intention-to-treat analysis [40]. TaTME reduced conversion to open surgery from 20% to 2%, while 30-day morbidity, pathological quality, and local recurrence were similar [40]. The modest sample and experienced participating teams limit wider inference. TaLaR provides the strongest current randomized support for oncological feasibility in a controlled implementation setting. After surgeon credentialing, video review, and structured training, 1,115 patients were enrolled across 16 centers [14]. Three-year disease-free survival was 82.1% after TaTME and 79.4% after laparoscopic TME, meeting the noninferiority criterion [14]. Local recurrence was 3.6% versus 4.4%, and overall survival was 92.6% versus 90.7% [14]. The trial therefore supports TaTME when expertise and quality control are explicit components of care. COLOR III extends this conditional evidence to an international multicenter setting. Under pretrial video-based competency assessment and centralized eligibility review, 90-day morbidity, anastomotic leakage, macroscopic specimen completeness, and margin involvement were similar across 28 hospitals [41]. Conversion was less frequent with TaTME [41]. These secondary endpoints support short-term safety within a controlled program, while follow-up for the 3-year local-recurrence primary endpoint remains ongoing. Direct randomized comparison between rTME and TaTME has also begun to emerge. In the single-center TARO trial, 108 patients with cT1-3N0-2M0 mid-to-low rectal cancer were randomized to either approach [33]. The composite pathological success rate, defined as complete TME with clear CRM and DRM, was 98.1% after TaTME and 94.4% after rTME, without a statistically significant between-group difference [33]. However, TARO enrolled a general mid-to-low rectal cancer population rather than a prespecified composite difficult-pelvis subgroup, and its results are currently available only as a conference abstract [33]. Pooled randomized evidence reinforces pathological feasibility without identifying a uniformly superior route. A meta-analysis of four randomized trials comparing laparoscopic TME with and without transanal dissection found fewer conversions and a higher rate of complete TME specimens with transanal dissection [42]. CRM positivity, DRM positivity, anastomotic leakage, and overall complications did not differ significantly [42]. A slightly lower lymph-node yield after transanal dissection shows that individual pathological endpoints may favor different approaches. Prospective cohorts provide follow-up beyond randomized eligibility but cannot determine comparative effectiveness. A four-center study of 173 patients reported complete TME in 72.8%, CRM positivity in 1.4%, DRM positivity in 1.1%, and 2-year disease-free survival of 88% [43]. A North American phase II study reported complete or near-complete TME in 90% of 100 patients and positive margins in two patients [44]. At a median 50.9 months, its companion report estimated 3-year disease-free survival at 84.6% and documented two locoregional recurrences [45]. Across study designs, the evidence supports a conditional rather than universal role for TaTME. Randomized trials, registries, and prospective cohorts reported acceptable oncological and pathological outcomes when trained teams operated within structured quality-assurance programs [12, 14, 33, 37, 40–45]. However, differences in credentialing, case mix, endpoint definitions, and implementation maturity limit the generalizability of these findings. Table 3 shows both the breadth and the limits of the TaTME evidence base. It includes major registry analyses, prospective cohorts, randomized trials, and direct comparisons [12, 14, 23, 29–33, 37, 40–46]. Source-defined complete-TME estimates ranged from 72.8% to 100%, whereas R0 resection was often not reported separately. Overlapping registry reports were retained to show evidence development, not treated as independent cohorts. The table therefore supports selective feasibility when distal management is constrained, not a claim of routine superiority. Robot-assisted and hybrid transanal platforms: technical evolution Robot-assisted transanal platforms expand the technical design space of TaTME, but current evidence remains proof-of-concept. Published R-TaTME, hybrid, and single-port reports show that robotic systems can be adapted to transanal dissection [47–51]. Their small samples and heterogeneity in platform, team configuration, pathological assessment, and follow-up prevent stable estimates of clinical benefit. Available studies have focused on selected very low tumors and technically demanding cases rather than routine practice [15, 16, 47–51]. The TARO trial reported an early randomized comparison of rTME and TaTME in a general mid-to-low rectal cancer population [33]. However, it did not recruit a prospectively defined composite difficult-pelvis subgroup and is currently available only as a conference abstract [33]. No head-to-head randomized trial has specifically compared rTME with TaTME in patients with a composite difficult-pelvis phenotype. Nor has a robotic transanal platform been randomized against established rTME or conventional TaTME [15, 16, 33, 47–51]. Table 4 therefore summarizes early pathological outcomes as evidence of technical development, not comparative effectiveness. Table 4 makes this evidence boundary visible. The included studies enrolled only 2–27 patients, and the reports by Monsellato, Ye, and Marks primarily established technical feasibility [48–50]. Hu et al. observed CRM involvement in 3 of 20 patients [47]. Ando et al. reported one radial-margin-positive and one distal-margin-positive case in a 27-patient hybrid cohort [51]. Taken together, these early studies provide proof-of-concept for robot-assisted transanal surgery and support its prospective evaluation in carefully selected difficult cases [47–51]. Discussion Repositioning TaTME in the robotic era: refinement rather than replacement Current evidence does not identify either rTME or TaTME as comprehensively superior. Instead, it supports repositioning TaTME from a broadly proposed alternative to a selectively retained approach. rTME may serve as the principal transabdominal strategy when distal exposure, dissection, and transection remain feasible from above. TaTME may retain value when a very low tumor and overlapping difficult-pelvis factors create a substantive distal technical constraint. The comparative syntheses support complementary rather than competing strengths. Butterworth et al. identified only two direct comparisons among 62 studies; pooled results favored TaTME for CRM positivity and rTME for complete TME [13]. Later reviews reported either a higher complete-TME rate with rTME or broadly similar perioperative, oncological, and functional outcomes [52–54]. Because the underlying studies were heterogeneous and predominantly nonrandomized, these analyses cannot identify a true treatment advantage within specific difficult-pelvis subgroups. A Bayesian network meta-analysis of 27 randomized trials involving 8,696 patients provided a broader pathological comparison [55]. Both robotic and transanal resections had lower odds of non-complete TME than laparoscopy; TaTME had lower CRM positivity, whereas rTME yielded more lymph nodes [55]. However, the rTME–TaTME contrast remained indirect and therefore cannot determine the preferred approach for a specific difficult-pelvis phenotype. Large experienced-center cohorts reached a similar clinical conclusion. In a population-based study of 617 low anterior resections, adjusted 3-year overall survival, disease-free survival, and local recurrence did not differ among laparoscopic, robotic, and transanal approaches [56]. Retrospective center-based allocation and exclusion of abdominoperineal resections limit route-specific inference. Nevertheless, the findings suggest that mature expertise and patient selection may be at least as important as platform choice. The available direct transition cohort is also compatible with complementary roles. Among 37 propensity-matched pairs, CRM and DRM involvement, lymph-node yield, and 3-year overall and progression-free survival were similar [32]. TaTME showed a nonsignificant trend toward a longer distal margin, whereas rTME was associated with less blood loss and a shorter hospital stay [32]. Temporal separation between the procedures, imbalanced enhanced-recovery use, and unavailable TME grading limit causal interpretation. Given these constraints, rTME appears suited to cases manageable from above, whereas TaTME may remain useful when distal exposure or transection is genuinely restricted. Taken together, the evidence supports refinement rather than replacement [13, 23, 24, 32, 33, 52–57]. rTME may cover most cases in which distal management remains feasible and controllable through the abdomen. TaTME should not be used as a routine alternative for all low rectal cancers, but may be selectively retained for very low tumors and composite difficult-pelvis scenarios involving substantive distal constraints. This is an evidence-informed framework for patient selection, not a validated treatment algorithm. The 2026 joint EAES, ESCP, and ESGAR guideline is consistent with this stratified position. Using GRADE, it recommends TaTME for low and selected mid-rectal cancers only in high-volume centers with dedicated expertise [58]. When such expertise is unavailable, it recommends against TaTME and identifies rTME as an alternative [58]. Because the supporting comparisons primarily involved laparoscopic TME, the guideline does not establish a comprehensive advantage of TaTME over rTME. Instead, it makes patient selection, surgeon capability, and institutional conditions part of the indication. Within this framework, rTME may be considered first when distal dissection and transection remain controllable through the abdomen [20–27]. Male sex, obesity, or a narrow pelvis alone should not prompt TaTME. A transanal approach may be considered when several factors converge to restrict distal control, particularly in very low tumors, and only when dedicated expertise is available [58]. Tumor stage, MRI-predicted margins, baseline anal function, patient preference, surgeon experience, and platform availability should also inform the final decision [3, 4, 58]. Quality assurance and functional outcomes For TaTME, implementation is part of the intervention rather than a separate logistical concern. The bottom-up orientation introduces specific risks involving the urethra, genital structures, pelvic plexus, and lateral attachments [35, 36]. The Norwegian suspension [39] and experience-dependent registry outcomes [38] show that case selection, supervision, institutional volume, and outcome monitoring can materially influence safety. Quality assurance must therefore be expressed as concrete competencies and institutional processes. Published curricula require prior competence in laparoscopic colorectal and transanal surgery, simulation, proctorship, specimen review, and registry follow-up [35]. International guidance adds center organization, quality indicators, and referral pathways [36]. The 2026 multidisciplinary guideline accordingly restricts TaTME to high-volume centers with dedicated expertise and identifies rTME as an alternative when expertise is unavailable [58]. Learning-curve evidence supports continuous competency assessment rather than a universal case-number threshold. A systematic review estimated 36–54 procedures in studies using risk-adjusted cumulative sum analyses, but methodological quality was low and estimates were heterogeneous [59]. In a multicenter external audit of 624 cases, early implementation was associated with more local recurrence, and outcomes improved with institutional experience [60]. These findings support staged assessment, proctoring, video review, and training within high-volume centers [35, 36, 59–61]. Technical capability should not be interpreted as durable functional benefit. A 2024 systematic review found no consistent long-term difference among routes in urinary, sexual, bowel, or quality-of-life outcomes [62]. Only a short-term urinary measure favored robotic surgery [62]. A 102-patient nonrandomized study reported faster early recovery and greater functional satisfaction after robotic surgery, but short follow-up limited causal inference [63]. Future studies should use validated instruments and adjust for baseline function, neoadjuvant treatment, anastomotic height, and diversion. Future directions: from procedural competition to individualized selection and platform-based development Robotics may both contract the routine role of TaTME and support its technical evolution. Improved transabdominal dissection may reduce the need for conventional TaTME when distal management is controllable from above. Conversely, robotic assistance during the abdominal phase, transanal phase, or both may create options for selected distal constraints. Randomized and multicenter evidence supports the first trajectory, whereas the second remains based mainly on feasibility studies [15, 20–27, 47–51]. Future research should replace broad procedural competition with prespecified questions about who benefits from each route. A priority design would be a multicenter randomized trial comparing rTME with TaTME in patients with a prospectively defined composite difficult-pelvis phenotype. Eligibility could require at least two prespecified factors, such as a deep or narrow pelvis on preoperative MRI, obesity, a very low or bulky tumor, threatened mesorectal fascia, or marked fibrosis after neoadjuvant treatment. Both procedures should be performed by credentialed surgeons, with randomization stratified by center, tumor height, and neoadjuvant treatment. A suitable primary endpoint would be successful oncological resection, defined as a complete TME specimen with uninvolved CRM and DRM. Key secondary outcomes should include conversion, major morbidity, anastomotic failure, sphincter preservation, LARS, urinary and sexual function, quality of life, cost-effectiveness, and 3-year local recurrence. Such a trial would test whether TaTME adds clinically meaningful value when distal management remains difficult despite an experienced robotic transabdominal approach. Robotic transanal platforms also require review of unedited operative video, prospective registries, and long-term follow-up before technical gains can be interpreted as patient benefit. Limitations of the current evidence The proposed framework is constrained by the design and heterogeneity of the available evidence. This structured narrative review searched three databases and prioritized randomized trials, large cohorts, systematic reviews, and guidelines. It was not a systematic review and did not apply a formal study-level risk-of-bias instrument. Tables 2, 3 and 4 are structured evidence maps rather than exhaustive quantitative syntheses. Differences in eligibility, operative configuration, pathology definitions, denominators, and center experience precluded pooling. Full-length direct rTME-TaTME evidence remains predominantly observational. The only randomized report identified was a single-center conference abstract that did not target a predefined difficult-pelvis phenotype [33]. Robot-assisted transanal evidence is likewise dominated by small feasibility series. Prospective evaluation in prespecified difficult-pelvis subgroups is therefore required. Conclusions Robotic transabdominal TME may narrow the routine role of conventional TaTME without making the transanal route obsolete. Randomized and multicenter evidence supports rTME when distal dissection and transection remain feasible and controllable from above. TaTME retains a selective role when very low tumor location and overlapping difficult-pelvis factors create a substantive distal technical constraint. The role of TaTME in the robotic era should therefore be one of selective retention rather than broad substitution. This position depends on specialist expertise, structured quality assurance, and patient-level selection, and it is not yet a validated algorithm. Robot-assisted, hybrid, single-port, and flexible transanal platforms may extend technical options for selected cases. Their clinical value requires prospective comparison and long-term oncological, functional, and cost-effectiveness evaluation. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1